Company Overview of IFM Therapeutics, Inc.
IFM Therapeutics, Inc., a biopharmaceutical company, develops a portfolio of small molecules targeting the innate immune system for the treatment of cancer and inflammatory disorders. It focuses on transformative therapies to improve the lives of patients with serious and life threatening diseases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts with a subsidiary in Bonn, Germany. As of September 7, 2017, IFM Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
400 Technology Square
Cambridge, MA 02139
Founded in 2015
Key Executives for IFM Therapeutics, Inc.
IFM Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
August 3, 2017
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|NYC2012, Inc.||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact IFM Therapeutics, Inc., please visit ifmthera.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.